MASH Mouse Model Selection 2026: GAN vs CDA-HFD vs STAM
A practical decision matrix for selecting the optimal MASH mouse model based on drug mechanism of action. Compare GAN diet, CDA-HFD, CCl4, STAM and more.
Introduction: "Which Model Should I Use?"
In MASH (metabolic dysfunction-associated steatohepatitis) drug discovery, selecting the right preclinical animal model for a given drug candidate is one of the first — and most consequential — decisions a project team must make.
More than ten distinct MASH mouse models are currently available, each recapitulating different pathological mechanisms, running on different timelines, and offering different levels of clinical translatability. A poor model choice at the preclinical stage can lead directly to the "Lost in Translation" problem — promising preclinical efficacy data that fail to replicate in Phase 2b clinical trials.
This article differs from general model overviews (→ MASH Model Overview) or head-to-head comparisons of specific models (→ AMLN Diet vs. GAN Diet). Instead, it provides a mechanism-of-action (MoA)-driven decision matrix designed to help drug discovery program leaders and project managers rapidly identify the optimal model strategy for their compound.
Quick Answer: Select a MASH model by MoA. (1) Metabolic modulators (GLP-1, THR-β, FXR) → GAN diet (16–24 wk; reproduces obesity, IR, dyslipidemia); (2) Anti-fibrotics (TGF-β, LOXL2) → CCl4 (4–8 wk; isolates core fibrogenesis); (3) Anti-inflammatories (CCR2/5, ASK1) → CDA-HFD (6–12 wk; potent inflammatory microenvironment); (4) Dual pharmacology → GAN diet + CCl4. No single model recapitulates the full human MASH spectrum; as established preclinical best practice, complementary use of multiple models is recommended. Tier 1 endpoints are NAS, fibrosis stage, and hydroxyproline — align them with the Phase 2b/3 primary endpoint.
1. Quick Reference: MoA-Based Model Selection Decision Table
Start with the bottom line. Use the table below to identify recommended models based on your drug candidate's MoA.
| Drug MoA | First-Choice Model | Complementary Model | Rationale |
|---|---|---|---|
| Metabolic improvement (GLP-1, GIP/GLP-1, THR-β, FXR) | GAN diet | WD (Western Diet) | Reproduces obesity, IR, and dyslipidemia — ideal for detecting metabolic efficacy |
| Anti-fibrotic (TGF-β inhibitor, LOXL2 inhibitor, HSC-targeted) | CCl4 | WD+CCl4 | Clean fibrogenesis pathway; reaches F3 rapidly |
| Anti-inflammatory (CCR2/5 inhibitor, ASK1 inhibitor, NF-κB-targeted) | CDA-HFD | GAN diet | Generates a robust inflammatory and fibrotic microenvironment in a short timeframe |
| Lipid metabolism (ACC inhibitor, SCD1 inhibitor, DGAT2 inhibitor) | GAN diet | CDA-HFD | Recapitulates systemic lipid metabolism dysfunction |
| HCC prevention / late-stage complications (immune checkpoint, etc.) | STAM | GAN diet (long-term) | Reliable MASH-to-HCC progression |
| Dual pharmacology / combination MoA | GAN diet + CCl4 | WD+CCl4 | Evaluates metabolic background and severe fibrosis simultaneously |
Key principle: No single model recapitulates the full spectrum of human MASH. Preclinical best practice and field consensus support the complementary use of multiple models (note that neither FDA nor EMA has issued MASH-specific guidance explicitly mandating multi-model use).
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Major MASH Models at a Glance
Diet-Induced Models
GAN Diet (Gubra-Amylin NASH Diet) — High fat (40 kcal% palm oil) + high fructose + high cholesterol (2%). Reaches F1–F2 in 16–20 weeks. Produces pronounced obesity, insulin resistance (IR), and dyslipidemia, giving it the highest overall clinical translatability[1]. Inter-individual variability is substantial, making biopsy-confirmed enrollment advisable. Note that its predecessor, the AMLN diet, was discontinued following a 2018 FDA regulatory action; most programs have since transitioned to the GAN diet (→ AMLN vs. GAN comparison).
CDA-HFD (Choline-Deficient, High-Fat Diet) — Reaches F2–F3 in as few as 6–12 weeks, making it one of the fastest models available. However, it induces weight loss and does not produce IR, limiting clinical translatability to fibrosis and inflammation endpoints only. Best suited for high-throughput screening of anti-fibrotic and anti-inflammatory agents[2].
Western Diet (WD) — Reaches F1–F2 in 16–24 weeks. Moderate obesity and IR. Fibrosis can be accelerated by combining with CCl4 (WD+CCl4).
Chemically Induced Models
CCl4 (Carbon Tetrachloride) — Intraperitoneal injection (twice weekly) reaches F2–F3 in 4–6 weeks and F4 in 8–12 weeks — the fastest fibrosis induction available. No metabolic phenotype, but cleanly recapitulates the core fibrogenesis cascade: HSC activation → myofibroblast differentiation → collagen deposition[3].
TAA (Thioacetamide) — Administered in drinking water; reaches F2–F3 in 6–8 weeks. Produces prominent periductular fibrosis. Oral administration simplifies handling.
Combination Models
WD+CCl4 — Western diet feeding combined with CCl4 injection reaches F3–F4 in 12–16 weeks. Combines a metabolic background with severe fibrosis[4].
STAM (STZ + High-Fat Diet) — Neonatal STZ injection followed by high-fat diet. Reaches F1–F2 by week 9 and HCC by weeks 16–20. Produces hyperglycemia but only mild obesity. Particularly suitable for evaluating "lean MASH" (prevalent in Asian populations) and MASH-to-HCC progression[5].
3. Recommended Model Strategies by Drug Target (MoA)
3-1. Metabolic Modulators (GLP-1 Receptor Agonists, THR-β Agonists, FXR Agonists)
Drugs that improve liver pathology through systemic metabolic correction require a model that faithfully reproduces obesity, insulin resistance, and dyslipidemia.
- Recommended: GAN diet model (16–24 weeks of feeding)
- Rationale: The GAN diet model was used in preclinical evaluation of semaglutide (Novo Nordisk), and the directionality of body weight reduction, NAS improvement, and hepatic fat reduction was consistent with human clinical outcomes[6]
- See also: GLP-1 Receptor Agonists and Fibrosis: Beyond Semaglutide
For THR-β agonists (e.g., resmetirom), evaluation requires capturing thyroid hormone pathway-mediated hepatic fat reduction, so a GAN diet model with sufficient steatosis development (≥20 weeks) is recommended.
3-2. Anti-Fibrotic Agents (TGF-β Inhibitors, LOXL2 Inhibitors, Integrin Inhibitors)
Drugs directly targeting the fibrosis cascade require a model that isolates fibrogenesis from metabolic confounders, enabling high-fidelity assessment of anti-fibrotic activity.
- Recommended: CCl4 model (4–8 weeks of dosing)
- Rationale: The CCl4 model cleanly recapitulates the core fibrosis pathway — hepatic stellate cell (HSC) activation → myofibroblast differentiation → collagen production
- Fibrosis assessment: Combined use of Sirius Red staining and hydroxyproline quantification is recommended
- Complementary: Add WD+CCl4 to confirm efficacy in a metabolic background
3-3. Anti-Inflammatory Agents (CCR2/5 Inhibitors, ASK1 Inhibitors, Caspase Inhibitors)
Drugs targeting the hepatic inflammatory microenvironment require a model that generates robust inflammation within a short timeframe.
- Recommended: CDA-HFD model (6–12 weeks of feeding)
- Rationale: Choline deficiency induces endoplasmic reticulum stress and oxidative stress, driving potent macrophage infiltration and cytokine production
- Complementary: Add a GAN diet arm to confirm anti-inflammatory efficacy in a metabolic context
Practical note: In preclinical studies, cenicriviroc (a CCR2/5 inhibitor) showed pronounced anti-inflammatory activity in a CDA-HFD model. However, the compound failed to meet its primary endpoint in the Phase 3 AURORA trial. This case underscores the risk of relying exclusively on positive data from inflammation-dominant models without metabolic validation.
4. Comprehensive Model Comparison Matrix
| Parameter | GAN Diet | CDA-HFD | CCl4 | TAA | WD+CCl4 | STAM |
|---|---|---|---|---|---|---|
| Time to F2 fibrosis | 16–20 wk | 6–12 wk | 4–6 wk | 6–8 wk | 8–12 wk | 9 wk |
| Obesity | +++ | ✕ (weight loss) | ✕ | ✕ | + | ✕ |
| Insulin resistance | +++ | ✕ | ✕ | ✕ | + | Hyperglycemia (IR−) |
| Steatosis | +++ | +++ | + | + | ++ | ++ |
| Lobular inflammation | ++ | +++ | ++ | ++ | ++ | ++ |
| Hepatocyte ballooning | ++ | ++ | + | + | ++ | + |
| HCC progression | ++ (long-term) | + | ✕ | + | ✕ | +++ |
| Overall clinical translatability | +++ | + | + | + | ++ | ++ |
| Study cost | High (long housing) | Medium | Low | Low | Medium–High | Medium |
| Inter-animal variability | High | Medium | Low | Low | Medium | Low |
| Best-fit MoA | Metabolic modulators | Anti-inflammatory / anti-fibrotic | Anti-fibrotic | Anti-fibrotic | Dual MoA | HCC prevention |
+++ = Excellent / ++ = Good / + = Limited / ✕ = Not applicable
5. Biomarker Endpoint Design
Equally important to model selection is designing a biomarker strategy that aligns with clinical trial endpoints.
Essential Endpoints (Tier 1)
| Biomarker | Method | Clinical Relevance |
|---|---|---|
| NAS (NAFLD Activity Score) | Histological scoring (H&E) | Preclinical exploratory marker (FDA accelerated approval for resmetirom used "MASH resolution without worsening of fibrosis" or "fibrosis improvement ≥1 stage without worsening of NAS" as primary; ≥2-point NAS improvement is a secondary endpoint) |
| Fibrosis stage | Sirius Red staining + quantitative image analysis | Clinical primary endpoint (≥1-stage fibrosis improvement) |
| Hepatic collagen content | Hydroxyproline quantification | Biochemical confirmation of fibrosis |
| Hepatic triglyceride | Biochemical quantification | Indicator of steatosis resolution |
Recommended Endpoints (Tier 2)
| Biomarker | Method | Significance |
|---|---|---|
| Serum ALT/AST | Clinical chemistry | Hepatocellular injury monitoring |
| αSMA immunostaining | IHC + quantification | Marker of HSC activation |
| Col1a1, Acta2, Tgfb1 gene expression | RT-qPCR | Fibrosis-related gene modulation |
| F4/80, CD68 immunostaining | IHC + quantification | Macrophage infiltration assessment |
Clinical Translation Enhancement (Tier 3)
To bridge preclinical and clinical biomarker data, consider adding serum Pro-C3 (a fibrogenesis marker measurable in mice), serum CK-18 (M30/M65) (apoptosis marker), and hepatic transcriptomics (RNA-seq) to assess gene expression concordance with human MASH liver tissue.
6. Study Design Timeline Examples
Example 1: PoC Study for a Metabolic Modulator (GLP-1 Agonist)
GAN diet feeding for 24 weeks → liver biopsy (disease confirmation + stratified randomization) → 8-week drug treatment → terminal analysis. Groups: vehicle, low-dose, high-dose, and positive control (n=12–15 per group). At week 24, only animals with NAS ≥ 5 and F ≥ 1 on biopsy are enrolled, ensuring a uniform baseline.
Example 2: Anti-Fibrotic Screening Study
CCl4 dosing initiated (0.5 mL/kg, twice weekly i.p.) → drug treatment started at week 2 in parallel → terminal analysis at weeks 6–8. Groups: normal control, vehicle, and drug-treated (n=8–10 per group). A "therapeutic" design — where drug treatment overlaps with ongoing CCl4 — enhances clinical relevance.
Example 3: Comprehensive Dual-Pharmacology Evaluation
Run Study A (metabolic assessment: GAN diet 24 weeks + 8-week treatment) and Study B (fibrosis assessment: CDA-HFD 6 weeks + 6-week treatment) in parallel, building evidence for both metabolic improvement and anti-fibrotic activity.
7. Key Considerations When Engaging a CRO
When outsourcing MASH preclinical studies to a contract research organization, confirming the following points helps ensure study quality and data reliability.
Model Establishment Track Record
- Availability of historical control data for the target model and reproducibility of fibrosis stages
- Established standard protocols for mouse strain (C57BL/6J vs. C57BL/6N) and age at study initiation
Pathology Assessment Infrastructure
- Blinded scoring (NAS, fibrosis stage) capability and workflow
- Automated, standardized Sirius Red quantitative image analysis pipeline
- Access to pathologists with hepatic pathology expertise
Liver Biopsy and Data Quality
- Intra-operative liver biopsy technique and survival rate data for GAN diet models
- Digital scanning and sharing of histopathology images; raw data delivery formats
- Housing capacity for running multiple models concurrently
8. Summary: Three Principles for Model Selection
- MoA first: Choose the model that is most sensitive to your compound's mechanism of action — not the most popular model in the field.
- Complementary multi-model strategy: Combine a metabolic model (GAN diet) with a fibrosis-focused model (CCl4 or CDA-HFD) to maximize clinical translatability.
- Align with clinical endpoints: Incorporate the same evaluation axes used in Phase 2b/3 primary endpoints — NAS improvement, fibrosis stage regression — into your preclinical study design.
The MASH therapeutic pipeline is expanding rapidly (→ MASH Therapeutic Landscape 2025), and as competition intensifies, appropriate preclinical model selection has never been more critical. We hope the decision matrix presented here serves as a practical tool for strategic decision-making in your drug discovery program.
FAQ
Q1: How do I choose between different MASH mouse models (AMLN, GAN, STAM, CDAHFD)?
Select based on your evaluation goal. For short-term fibrosis-only readouts, use CDAHFD (4-8 weeks). For human-like metabolic derangement with obesity, choose GAN diet (20-30 weeks). For progression to hepatocellular carcinoma, use STAM. For general-purpose diet-induced MASH, AMLN diet is versatile.
Q2: Which MASH model best mimics human disease?
By gene expression profile similarity, the GAN diet model most closely resembles human MASH (Teufel 2016), reliably reproducing fibrosis progression with metabolic syndrome features. However, its long study duration (20+ weeks) makes it unsuitable for compound screening.
Q3: How long does each MASH model take?
Study duration varies widely: CDAHFD 4-8 weeks (fastest), STAM 6-12 weeks, AMLN diet 16-24 weeks, GAN diet 20-30 weeks. Shorter models induce stronger fibrosis but sacrifice metabolic reproducibility.
Q4: Can a single MASH model evaluate steatosis, inflammation, and fibrosis together?
GAN and AMLN diets reproduce the full progression (fat accumulation → inflammation → fibrosis) and allow MOA-specific compound evaluation across stages. In contrast, CDAHFD induces strong fibrosis but weak metabolic phenotypes and is not ideal for comprehensive assessment.
Q5: What staining and quantification methods are standard for final evaluation?
Sirius Red staining (fibrotic area %) combined with hydroxyproline quantification (absolute collagen content) is the standard approach. See Sirius Red Staining guide and Hydroxyproline Quantification for protocols.
Related Articles
- MASH Model Overview: A Preclinical Model Strategy Guided by Clinical Relevance
- AMLN Diet vs. GAN Diet: Which Should You Choose?
- Sirius Red Staining: Principles and Analysis for Fibrosis Assessment
- Hydroxyproline Quantification: Fundamentals of Collagen Measurement
- GLP-1 Receptor Agonists and Fibrosis: Beyond Semaglutide
- MASH Therapeutic Landscape 2025
References
1. Tølbøl KS, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24(2):179-194. PubMed
2. Matsumoto M, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94(2):93-103. PubMed
3. Tsuchida T, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69(2):385-395. PubMed
4. Teufel A, et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology. 2016;151(3):513-525.e0. PubMed
5. Fujii M, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46(3):141-152. PubMed
6. Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PubMed